cytochrome P450 family 2 subfamily C member 56, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP2C56P profile across patient tissues and cancer cell-line models. CYP2C56P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CYP2C56P is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, CYP2C56P RNA expression shows 5,413 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, and STAD as cancer lineages where CYP2C56P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2C56P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2C56P survival associations across molecular data types. CYP2C56P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2C56P RNA expression–survival associations across cancer types. High CYP2C56P expression shows unfavorable associations in UCEC, THYM, LIHC, ESCA, STAD and BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CYP2C56P RNA expression.
This table summarizes CYP2C56P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2C56P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2C56P shows lower tumor expression in STAD. The STAD box plot shows higher CYP2C56P RNA expression in normal versus tumor tissue (log2 FC = −0.038, t-test p = .039).
This table shows molecular features associated with CYP2C56P in patient tissues and cancer cell lines. In patient samples, CYP2C56P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
